MannKind Corporation heads into the final week of August with shorts rebuilding at the margin, institutions adding aggressively, and analysts pointing to a stock that trades at less than half its consensus target — a gap that has persisted all year without closing.
Short interest has quietly climbed over the past month. Bears hold roughly 9.8% of the free float, up about 7% from 30 days ago, with around 30 million shares now borrowed. The week-on-week move was modest — up less than 2% — but the one-month drift tells a more consistent story of renewed bearish positioning. Cost to borrow has jumped roughly 45% over the past week to 0.54%, the highest level since late July, though in absolute terms it remains low. Availability is comfortable at 228% — more than two shares available to borrow for every one already lent out — so the lending market is not close to stressed. The short score of 64.6 sits in a range it has occupied for most of the month, neither accelerating nor retreating. Options sentiment is mildly more defensive than usual, with the put/call ratio at 0.147, about 1.6 standard deviations above its 20-day average of 0.136, but this is a shallow market — the 52-week high PCR was 0.517, so current readings are far from fearful. Taken together, the positioning picture is cautious but not crowded.
The most striking data point this week is institutional, not bearish. Rubric Capital built a fresh 18-million-share position — equivalent to 5.6% of shares outstanding — in the quarter ending June 30. Deep Track Capital and Braidwell LP both initiated new stakes in the same quarter. Wellington Management added over 4.5 million shares. BlackRock, already the largest holder at just under 10% of shares, added another 3.5 million shares through July. The result is a holder list that is broadly expanding, with new specialist biotech and healthcare names showing up alongside the passive giants.
On the Street, the bull-bear divide is wide. Wells Fargo has been the most active voice, lifting its target from $11 to $14 at end of July before trimming back to $13 following the August earnings print — still implying more than 200% upside from the current $4.15 close. RBC Capital sits at the other end, at $4.75 with a neutral rating, reflecting concern about execution. The consensus mean target of $7.72 implies roughly 86% upside, but the dispersion is what matters: the range runs from near-current-price to $13, meaning analysts genuinely disagree about whether catalysts — the Afrezza pediatric approval and the new Furoscix ReadyFlow autoinjector cleared by the FDA in late July — translate into commercial traction. The EV/EBITDA multiple has compressed sharply, down around 43 points over 30 days, while the PE of roughly 42x has expanded. Factor scores rank short interest risk in the 17th percentile — meaning bearish positioning is lighter than most peers — though the EPS surprise rank of just 3rd percentile signals the company has consistently missed estimates.
Insider activity is a mild net positive but not a strong signal. CEO Michael Castagna sold about 47,000 shares at $4.09 in mid-July, and several other executives cleared smaller positions around the same time — routine stock award-related selling rather than conviction exits. Net insider activity over 90 days is a positive 740,000 shares, largely award-driven. Nothing here changes the thesis.
The stock gained 7.8% over the past week to $4.15 before giving back 2.6% on Friday. Next earnings are scheduled for early November. Between now and then, the key watch point is whether the three-product commercial engine — Afrezza, Furoscix, and V-Go — shows revenue momentum that justifies the gap between the current price and where the most constructive analysts have pitched their targets.
See the live data behind this article on ORTEX.
Open MNKD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
